Toni Martinez

🧬 Mutant p53 & therapy response - Weekly report 🔬 Highlight: Covalent agonists targeting p53 Y220C restore its function and suppress tumor growth - real progress toward drugging mutant p53. 👉 biomed.news/bims-p53act/la… @Bims_BiomedNews #p53 #Oncology

Mutant p53 & therapy response - weekly report 🧬 🔬 Highlight: TP53 mutations may predict poor response to taxane chemotherapy TP53 status isn’t just biology, it’s clinical. @Bims_BiomedNews #p53 #CancerResearch #Oncology biomed.news/bims-p53act/20…

🧬 New report: Mutant p53 & cancer therapy - TP53 CpG site mutations define an immune-activated tumor subtype and predict improved response to first-line chemoimmunotherapy in lung adenocarcinoma. @Bims_BiomedNews #p53 #CancerResearch #Immunotherapy biomed.news/bims-p53act/20…

🧬 New report: Mutant p53 & anti-cancer therapy response Highlights: - TP53 loss links mTOR activation and immune-cold MSS colorectal cancer - TP53 mutations associate with improved PFS with cetuximab+pembrolizumab in CRC @Bims_BiomedNews #p53 biomed.news/bims-p53act/20…

🧬New Mutant p53 & Cancer Research Report of the week! Highlights: - TP53-mut diffuse follicular lymphoma with cnLOH at 1p36 highlights molecular profiling. - Mut p53 rewires CXCL10, boosting CD8⁺ T cells and anti-PD-1 response. @Bims_BiomedNews biomed.news/bims-p53act/20…

New Mutant p53 & Cancer Therapy Response Report is out! 🧬 Highlights: • Lung-specific p53 mutants bind DNA but fail to transactivate • Rezatapopt shows Phase I activity in Y220C tumors @Bims_BiomedNews #p53 #CancerResearch #Oncology biomed.news/bims-p53act/20…

New weekly Mutant p53 & Anti-Cancer Therapy Response report out now 🧬🧠 This issue highlights: - Novel drug and prodrug candidates targeting TP53 mutations - TP53-dependent cell fate in glioblastoma @Bims_BiomedNews biomed.news/bims-p53act/20… #p53 #Oncology #CancerResearch

New week, new report 🧬 My weekly Mutant p53 & anti-cancer therapy response report is out. Fresh evidence on how TP53 mutations shape treatment response in cancer. @Bims_BiomedNews #p53 #Cancer #Oncology #CancerTherapy #BiomedsNews biomed.news/bims-p53act/20…

Nou article a #Docusalut: Hotspot mutant p53-R273H enhances mitochondrial biogenesis and cell migration in primary colorectal cancer in response to oxaliplatin hdl.handle.net/20.500.13003/2…  @idisbaib #PublicaSalutIB

Highlight: "Pro-ATO/Allicin Liposomes for Dual-Pathway Targeting of p53-Mutant Tumors" advanced.onlinelibrary.wiley.com/doi/10.1002/ad…

A new Biomeds News report is out 🚀 This week’s update on mutant p53 & anti-cancer therapy response - key papers, one place. @Bims_BiomedNews #p53 #CancerResearch #Oncology #BiomedsNews biomed.news/bims-p53act/20…

Nou article a #Docusalut: Hotspot mutant p53-R273H enhances mitochondrial biogenesis and cell migration in primary colorectal cancer in response to oxaliplatin  hdl.handle.net/20.500.13003/2…  @idisbaib #PublicaSalutIB

Highlight: "Efficacy of melflufen in multiple myeloma with mutated or deleted TP53" link.springer.com/article/10.118…

Here we go again! Kicking off 2026 🚀, my weekly report about mutant p53 and anti-cancer therapy response is out. @Bims_BiomedNews #p53 #Oncology #CancerTherapy #BiomedsNews biomed.news/bims-p53act/20…

Highlight: pubs.acs.org/doi/10.1021/ac…

Just before Christmas🎄, my weekly Biomeds News report is out. Growing evidence shows the clinical relevance of mutant p53 in treatment response, positioning it as a key axis in anticancer therapy. @Bims_BiomedNews #p53 #Oncology #biomedsnews biomed.news/bims-p53act/20…

Highlight: Integrative Multi-Omics Analysis Unveils the Molecular Mechanisms by Which TP53 Mutation Influence Early Decitabine Resistance in Myelodysplastic Syndrome onlinelibrary.wiley.com/doi/10.1002/jc…

🧬Mutant p53 & anticancer therapy - weekly update. A curated snapshot of recent studies on therapy response, resistance and tumour adaptation across cancers. biomed.news/bims-p53act/20… @Bims_BiomedNews #p53 #Oncology #CancerResearch

Taken together, these studies reinforce a clear signal: TP53 mutations are increasingly being explored as context-dependent therapeutic vulnerabilities, not just prognostic markers. #TargetedTherapy #DNADamage #Oncology

🧬 Our latest @Bims_BiomedNews report on mutant #p53 and anticancer therapy is out. Across multiple #Cancer types, recent studies highlight how TP53 #mutations intersect with tumor plasticity, DNA repair pathways, immune context and treatment response. biomed.news/bims-p53act/20…